Renal medullary carcinoma: the Bronx experience.

Renal medullary carcinoma: the Bronx experience. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Renal medullary carcinoma: the Bronx experience. Abstract Text:

A Ari Hakimi,Phillip T Koi,Paul M Milhoua,Netta M Blitman,Maomi Li,Vladimir Hugec,Janice P Dutcher,Reza Ghavamian,A Ari Hakimi,Phillip T Koi,Paul M Milhoua,Netta M Blitman,Maomi Li,Vladimir Hugec,Janice P Dutcher,Reza Ghavamian,

OBJECTIVES: Renal medullary carcinoma (RMC) is a devastating and extremely rare malignancy primarily afflicting young men with sickle cell trait. We present our clinical experience with 9 cases of RMC during a 10-year period and briefly review the published data. METHODS: A retrospective chart review of 9 cases of RMC during a 10-year period at our institutions was performed. The clinical patient characteristics, presentations, treatments, and outcomes were recorded. The radiographic images and pathologic specimens were reviewed. Applicable studies were selected from a Medline search. RESULTS: All 9 patients had sickle cell trait, the male/female ratio was 6:3, and the age range was 13 to 31 years. All the patients presented with flank pain, two thirds had hematuria, and 3 of the 9 patients presented with a palpable mass. Eight of the nine tumors were right sided, ranging from 4 to 12 cm in the greatest diameter. Of the 9 patients, 7 underwent radical nephrectomy. One patient was deemed to have unresectable disease by the operating surgeon, and one was given initial chemotherapy after biopsy of a metastatic lesion. The neoadjuvant therapies varied. Overall survival ranged from 4 to 16 months, with 2 patients still living at the last follow-up visit. CONCLUSIONS: Our urban setting likely explains our relatively large experience with this rare and extremely aggressive tumor. An early diagnosis is critical, and a high index of suspicion should be given to any individual with sickle cell trait and new-onset hematuria, especially in the setting of a right-sided mass. Prospective trials are needed for chemotherapy/immunotherapy, because surgical intervention alone is inadequate.

Renal medullary carcinoma: the Bronx experience. Publishing Authors By Initials

AA Hakimi,PT Koi,PM Milhoua,NM Blitman,M Li,V Hugec,JP Dutcher,R Ghavamian,AA Hakimi,PT Koi,PM Milhoua,NM Blitman,M Li,V Hugec,JP Dutcher,R Ghavamian,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Renal medullary carcinoma: the Bronx experience. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Urology

VOLUME: 70

Page Numbers: 878-82

Journal Abbreviation: Urology

ISSN: 1527-9995

DAY: 10

MONTH: Nov

YEAR: 2007

Renal medullary carcinoma: the Bronx experience. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 366151

Renal medullary carcinoma: the Bronx experience. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Renal medullary carcinoma: the Bronx experience. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Renal medullary carcinoma: the Bronx experience.

AFFILIATION: Department of Urology, Montefiore Medical Center, Bronx, New York 10467, USA. ahakimi@montefiore.org

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Urology

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Renal medullary carcinoma: the Bronx experience Related Publications

• Editorial comment.
• Issue of prostate gland size, laparoscopic radical prostatectomy, and continence revisited.
• Laparoscopic nephrectomy for the management of renal medullary carcinoma in a child.
• Laparoscopic partial nephrectomy in the treatment of renal cell carcinoma: a minimally invasive means to nephron preservation.
• Minimally invasive approaches to prostate cancer: a review of the current literature.
• Renal medullary carcinoma: the Bronx experience.